The association of body composition parameters and adverse events in women receiving chemotherapy for early breast cancer

Aleixo, Gabriel F. P.; Shachar, Shlomit Strulov; Deal, Allison M.; Nyrop, Kirsten A.; Muss, Hyman B.; Chen, Y. T.; Yu, Hyeon; Williams, Grant R.

doi:10.1007/s10549-020-05731-1

Cited by 14 publications

(5 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…reported the proportion of patients low SMI across multiple thresholds. 22 An SMI below the defined threshold was reported in 40.2% ( n = 15, 103 patients). Across the entire cohort, the median proportion of patients with low SMI was 43% (30.1–57.1).…”

Section: Resultsmentioning

confidence: 95%

See 1 more Smart Citation

Computed tomography‐defined low skeletal muscle index and density in cancer patients: observations from a systematic review

McGovern

Dolan

Horgan

et al. 2021

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

Background Computed tomography (CT) analysis of body composition has garnered interest as a potential prognostic tool in those with cancer. A range of pre‐defined thresholds currently exist within the literature to define low skeletal muscle mass and density. The aim of the present systematic review was to assess the prevalence of low skeletal muscle index (SMI) and density (SMD) within the literature, across a range of common solid tumours. Methods A systematic search of PubMed was carried out to identify studies reporting CT analysis of SMI and SMD in patients with colorectal, oesophageal, gastric, hepatobiliary, pancreatic, breast, and lung cancer. The type of cancer, whether curative or non‐curative disease, the anthropomorphic parameter studied, threshold used to define low SMI and SMD, and the prevalence of these anthropomorphic measurements within the population were recorded. Results Of the 160 studies included, 156 reported an assessment of SMI and 35 reported assessment of SMD. The median prevalence of low SMI was 43% (30.1–57.1) and low SMD 49.4% (31.7–58.5) across the entire cohort. There was little variation in the prevalence of low SMI and SMD when studies were divided into curative and non‐curative cohorts—40.7% (27.5–51.3) vs. 48.4% (30.9–60.1) and 37.8% (32.2–52.2) vs. 55.3% (38.5–64.7) respectively. When divided into colorectal, oesophageal, gastric, hepatobiliary, pancreatic, breast and lung cancers, similar prevalence of low SMI (46.0% %, 49.8%, 35.7%, 41.1%, 32.3%, 34%, and 49.5%) and low SMD were also observed (52.1%, 54.3%, 71.2%, 56.8%, 55.3%, and 52.6%). This was maintained when studies were stratified into cohorts by threshold used—low SMI (Martin 48.9%, Prado 49.9%, and Others 36.0%) and low SMD (Martin 52.4% and Others 48.6%). Conclusions Low SMI and SMD are endemic across a range of cancer types and disease stage, challenging pre‐existing dogma of the determinants of prevalence.

show abstract

Section: Resultsmentioning

confidence: 95%

“…One study by Aleixo et al . reported the proportion of patients low SMI across multiple thresholds 22 . An SMI below the defined threshold was reported in 40.2% ( n = 15, 103 patients).…”

Section: Resultsmentioning

confidence: 99%

Computed tomography‐defined low skeletal muscle index and density in cancer patients: observations from a systematic review

McGovern

Dolan

Horgan

et al. 2021

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

show abstract

“…Sarcopenia, defined as a condition with loss of muscle mass in older adults [ 9 ], is correlated with poor survival in various solid malignancies, including breast cancer [ 8 , 10 – 16 ]. In addition to the importance of sarcopenia at the beginning of cancer treatment, skeletal muscle loss during palliative chemotherapy has recently been shown to be associated with reduced survival in patients with gastrointestinal cancer [ 17 – 22 ].…”

Section: Introductionmentioning

confidence: 99%

Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer

et al. 2022

View full text Add to dashboard Cite

Background The skeletal muscle index (SMI), which is calculated as the ratio of skeletal muscle area at the third lumbar vertebral level divided by height squared, has been considered a prognostic factor in patients with breast cancer. However, the prognostic impact of changes in SMI during treatment remains unclear. This study aimed to evaluate the influence of SMI changes in patients with breast cancer undergoing neoadjuvant chemotherapy (NAC). Methods We reviewed patients with breast cancer who underwent NAC and subsequent surgery for breast cancer between 2010 and 2017. The rate of SMI change during NAC was calculated, and the association between SMI changes and prognosis was retrospectively analyzed. Results In total, 141 patients were evaluated. 48 (34.0%), 53 (37.6%), and 40 (28.4%) patients exhibited increased (≥ 3%), maintained (− 3% <, < 3%), and decreased (− 3% ≥) SMI during NAC, respectively. The decreased SMI group showed significantly poorer disease-free survival than the maintained and increased SMI groups (hazard ratio [HR] 8.29, p < 0.001 for the decreased vs. increased SMI groups; HR 3.49, p < 0.001 for the decreased vs. maintained SMI groups). Moreover, decreased SMI was an independent risk factor for disease-free survival in multivariate analysis (HR 3.68, p < 0.01). Conclusions Skeletal muscle loss during NAC predicts poor prognosis. Our results underscore the importance of monitoring and maintaining skeletal muscle mass during NAC.

show abstract

“…changes in body composition during chemotherapy have an impact on patients' vital prognosis, as several studies have shown (1)(2)(3)(4)(5)(6)(7). The biochemical and anatomical model of body composition as described by Kaffel et al in 2021 demonstrates a model for analysing body composition, the components of which, notably adipose, muscle and water, are of vital importance during chemotherapy(8).…”

Section: Introductionmentioning

confidence: 99%

Body composition and metabolic profile during chemotherapy in early-stage breast and cervical cancer patients in Douala, Cameroon: A hospital-based study

Anaba,

Mboussi,

Bell

et al. 2024

Preprint

View full text Add to dashboard Cite

Changes in body composition during chemotherapy can negatively influence the prognosis of cancer patients. In order to assess changes in body composition in patients undergoing chemotherapy, a case-control study was conducted in the cobalt therapy departments of the Douala General Hospital. The overall objective of this study was to determine the impact of chemotherapy and stage of disease on changes in body composition in women with breast or cervical cancer followed at the oncology unit of Douala General Hospital. Muscle mass, body fat and body water percentages were measured by the bioimpedancemetry method and blood samples were collected for the measurement of albumin and creatinine concentrations. The results were analysed using SPSS version 16 for Windows (SPSS, IBM, Chicago, IL, USA). The mean age of the patients was 44.62 ± 11.23 years for breast cancer (BC) patients, 50.37 ± 10.78 years for cervical cancer (CC) patients and 46.11 ± 10.43 years for controls. Muscle mass, body fat and body water decreased significantly in cases compared to controls (respectively p = 0.0028, p = 0.004, p = 0.004). According to the stage of the disease when the two clinical groups were taken individually muscle mass decrease significantly between stage 1 to stage 2 in patients with BC (p = 0.001), but not in patient with CC (p = 0.84). Body fat and body water percentages decrease not significantly between stage 1 to stage 2 in the both cancer. Metabolically, creatinine concentrations were significantly elevated in both groups of patients compared with controls (p < 0.001), and albumin concentrations were significantly low (p < 0.001). In terms of disease stage, creatinine concentrations increased but not significantly between stage 1 and stage 2 in breast cancer patients (p = 0.08) and decreased non-significantly in cervical cancer patients (p = 0. 95). Albumin concentrations decreased significantly in cervical cancer patients (p = 0.01) between stage 1 and stage 2 but did not decrease significantly in breast cancer patients (p = 0.55). In conclusion, chemotherapy considerably altered the physical and metabolic body composition of breast and cervical cancer patients included in our study.

show abstract

The association of body composition parameters and adverse events in women receiving chemotherapy for early breast cancer

Cited by 14 publications

References 33 publications

Computed tomography‐defined low skeletal muscle index and density in cancer patients: observations from a systematic review

Computed tomography‐defined low skeletal muscle index and density in cancer patients: observations from a systematic review

Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer

Body composition and metabolic profile during chemotherapy in early-stage breast and cervical cancer patients in Douala, Cameroon: A hospital-based study

Contact Info

Product

Resources

About